UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants
- To find out if giving multi-agent chemotherapy in lower and more frequent doses to make
the timely delivery of chemotherapy cycles possible, will result in better treatment
outcomes
- To find out if changing the way the drugs are given during the transplant phase will
also result in fewer side effects, while still being effective
- To find out if giving treatment between transplants (called "inter-transplant therapy")
will prevent the myeloma from re-growing between transplants
- To find out if long-term maintenance therapy will result in longer remissions
- To find out what the effects (good and bad) of this overall treatment will be
- To learn more about the biology and genetics of multiple myeloma by performing imaging
tests and collecting blood, bone marrow aspirate and biopsies, and biopsies of lesions
seen on MRI or PET scans for research
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Accelerate and sustain, at 2 years from starting therapy
2 years
Yes
Saad Usmani, MD
Principal Investigator
UAMS
United States: Institutional Review Board
UARK 2008-02
NCT00869232
October 2008
October 2013
Name | Location |
---|---|
University of Arkansas for Medical Sciences | Little Rock, Arkansas 72205 |